(NASDAQ: PRAX) Praxis Precision Medicines's forecast annual revenue growth rate of 234.75% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.5%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.08%.
Praxis Precision Medicines's revenue in 2024 is $2,447,000.On average, 4 Wall Street analysts forecast PRAX's revenue for 2024 to be $45,672,304, with the lowest PRAX revenue forecast at $10,590,679, and the highest PRAX revenue forecast at $66,191,745. On average, 2 Wall Street analysts forecast PRAX's revenue for 2025 to be $58,513,503, with the lowest PRAX revenue forecast at $39,715,047, and the highest PRAX revenue forecast at $77,311,958.
In 2026, PRAX is forecast to generate $1,342,262,682 in revenue, with the lowest revenue forecast at $96,772,331 and the highest revenue forecast at $3,387,958,276.